Trials / Unknown
UnknownNCT03920605
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
Study on Optimized Treatment of Peginterferon Alfa 2a or 2b in Anti-virus Treatment Experienced Patients With Hepatitis b Virus Related Liver Fibrosis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 15 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.
Detailed description
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. But there still lacks of studies on peginterferon alfa 2a or 2b treatment in patients with HBV related liver fibrosis. We design this study to investigate optimized treatment of peginterferon alfa 2a/2b, comparing to nucleoside/nucleotide analogues, in anti-virus treatment experienced patients with HBV related liver fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir Disoproxil Fumarate | Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day. |
| DRUG | Peginterferon Alfa-2a | Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week. |
| DRUG | Peginterferon Alfa-2b | Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week. |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2021-10-30
- Completion
- 2021-12-31
- First posted
- 2019-04-19
- Last updated
- 2019-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03920605. Inclusion in this directory is not an endorsement.